InvestorsHub Logo
Followers 29
Posts 9421
Boards Moderated 0
Alias Born 04/30/2006

Re: opportunityknocking post# 23653

Monday, 10/19/2009 1:36:47 PM

Monday, October 19, 2009 1:36:47 PM

Post# of 30387
Opportunity stated: "Gold, do you want to still quote Dr Kramer after knowing that recaf paired with current markers gives ZERO false positives?"

Opportunity, you obviously did not even pay attention to what Dr. Kramer was stating. He was not addressing anything related to false positives. That is an entirely different subject.

What he was addressing was unnecessarily locating small early cancer that in fact may never become a problem for a person in their lifetime. This is exactly one of the problems PSA has. Not only does it have the false positives but we will not address that portion at all right now. The other problem with PSA is that it is finding all those early slow growing cancer that may never be a problem. Those cancer ARE IN FACT BENG TREATED. That is the problem Dr. Kramer is addressing.

Now, do you understand what Dr. Kramer is saying?

If RECAF did in fact work as advertised by Moro, it would detect most of those small slow growing cancers and it could become a huge problem with unnecessary treatment.

Dr. Kramer is not alone in addressing the problems of current screening and the harm it does. This is the direction the thought leaders in cancer diagnostics are going and the momentum is growing. Remember, I am not a doctor. I am just relating what I am reading and that is the trend I see. From that you can easily conclude that RECAF is NOT what the medical community wants for screening and that is where the big bucks are at.

DR70 has been approved for almost 1 1/2 years and no doctors are jumping on the bandwagon singing the praises of DR70 for even monitoring. This is a bad sign and investors here should take notice.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.